Semaglutide sold as a research peptide is a long, heavily modified molecule — which makes it harder to synthesise cleanly than most of a peptide catalogue and correspondingly easier to get wrong. This covers what it is, how the formats compare, and what a certificate has to demonstrate before the material is worth buying.
Proxiva Formulation DeskBlends, fill weights and multi-component products
Key takeaways
- Semaglutide is a 31-residue GLP-1 analogue carrying a fatty-acid chain attached via a linker — the modification is central to the molecule, not an accessory.
- Stocked as a lyophilised vial, as a 60mg/3ml pen, and as a kit. These price in different units and do not compare at a glance.
- Because the molecule is long and modified, the theoretical mass cannot be derived from a plain amino-acid sequence — a certificate reporting only a sequence was templated, not analysed.
- It is a single GLP-1 receptor agonist, distinct from the dual and triple agonists sold alongside it.
- Cost per milligram is the only fair comparison, and it should be net peptide rather than gross fill weight.
What the molecule is
Semaglutide is an analogue of glucagon-like peptide-1, a 31-amino-acid backbone based on the native GLP-1 sequence with three deliberate changes.
- A substitution at position 8. Native GLP-1 is cleaved rapidly by dipeptidyl peptidase-4, which attacks near the N-terminus. Replacing the vulnerable residue with one the enzyme does not accept removes that route of degradation.
- A fatty-acid chain attached to a lysine side chain via a short spacer. This promotes reversible binding to serum albumin, which slows clearance substantially.
- A further substitution that prevents the fatty acid attaching at an unintended position during synthesis.
That second modification is the defining feature. Native GLP-1 has a half-life measured in minutes; the albumin-binding fatty acid is what turns a transient signal into a molecule stable enough to study.
It also has a direct consequence for verification, covered below: the finished molecule is not a plain peptide, so its mass is not something you can calculate from the sequence alone.
Where it sits among the agonists
Compounds in this class are distinguished by how many receptors they engage, and catalogue naming often obscures rather than clarifies that.
| Receptors engaged | Compound | In this catalogue |
|---|---|---|
| GLP-1 only | Semaglutide | GLP-1 S |
| GLP-1 + GIP | Tirzepatide | GLP-2 T |
| GLP-1 + GIP + glucagon | Retatrutide | GLP-3 R |
Semaglutide is the single agonist — it engages the GLP-1 receptor only. The dual and triple agonists add targets, and each addition is a harder design and synthesis problem, which is reflected in their pricing rather than in scarcity.
The catalogue labels count receptors, not receptor types. There is no "GLP-2 receptor" being referenced by the dual agonist's name and no GLP-3 receptor at all — a point covered further in the GLP-3 pen guide.
Formats and what separates them
| Vial | 60mg/3ml pen | Kit | |
|---|---|---|---|
| State | Lyophilised powder | In solution | Multiple vials |
| Concentration | You set it | Fixed 20mg/ml | You set it |
| Stability clock | At reconstitution | At manufacture | At reconstitution |
| Best for | Adjustable work, long storage | Repeatable measurement | Volume |
| Reconstitution | Required | None | Required, per vial |
The pen arithmetic is simple: 60mg across 3ml is 20mg/ml, and it cannot be changed.
For this compound the stability difference deserves more weight than it would for a short peptide. Thirty-one residues plus a fatty-acid modification means more sites vulnerable to hydrolysis and oxidation, so extended time in solution costs more here. A pen's contents have been dissolved since it was filled, and the fill date is frequently undisclosed — ask, because the willingness to answer is itself informative. Full treatment in pens versus vials.
Analytical requirements for a modified 31-mer
Two requirements follow from the molecule's construction and are not optional at this chain length.
Mass must be evaluated against the modified species
The finished molecule is backbone plus fatty acid plus linker. Its theoretical mass is therefore not derivable from the amino-acid sequence alone, and a reported value must be compared against the modified figure. A certificate presenting a bare sequence and a mass computed from it has been generated against a template for unmodified peptides — a structural error that invalidates the document rather than a formatting one.
Impurity distribution over impurity total
Coupling efficiency compounds multiplicatively, so a 31-residue synthesis carries a materially lower crude yield than a short one. The deficit manifests as truncated chains differing from the target by a single residue, which co-elute at similar retention times. Consequently the informative quantity is the distribution of impurity across the trace, not the summed percentage: clustered peaks adjacent to the principal peak indicate unresolved truncations, a single symmetric peak indicates a controlled process. The reported figure is identical in both cases.
- Chromatogram supplied, not a summary figure
- Mass spectrometry referenced to the modified theoretical mass
- Lot identifier concordant with the container label
- Analysis performed by a laboratory independent of the synthesising facility
- Residual solvent quantification appropriate to the synthetic route
- Water and counterion content, which determine net peptide per unit mass
- For pre-filled formats: documentation of the fill lot, not solely the bulk lot
Each field is treated individually in how to read a certificate of analysis.
Why the albumin trick is worth understanding
The fatty-acid modification is the part of this molecule most often glossed over, and it is genuinely elegant chemistry worth a paragraph.
Serum albumin is the most abundant protein in blood plasma, and part of its normal job is transporting fatty acids. It has dedicated binding sites for them, and it circulates for weeks rather than minutes.
Attaching a fatty-acid chain to a peptide effectively gives that peptide a handle albumin will grip. The bound molecule is shielded from renal filtration and from the enzymes that would otherwise clear it, and because the binding is reversible, a small free fraction remains available at any moment. The albumin becomes a reservoir rather than a sink.
This is why the modification cannot be treated as an optional extra. Remove it and you have a different molecule with a completely different clearance profile — one closer to native GLP-1, which is to say one that would not be useful.
The same strategy appears elsewhere in peptide design. CJC-1295 in its DAC form uses a Drug Affinity Complex to achieve the same albumin binding, which is precisely why the DAC and no-DAC versions behave so differently — the point examined in our Ipamorelin versus CJC-1295 comparison. Different chemistry, identical objective.
For a buyer the practical upshot is that any certificate that does not account for the modification is describing a molecule you did not order.
Comparing prices honestly
Convert everything to cost per milligram before anything else. Vial, pen and kit are quoted in different units and their sticker prices rank them wrongly.
Then make two adjustments most buyers skip:
- Net rather than gross. HPLC purity measures UV-absorbing organic material only. Water and counterion are invisible to it, so a stated fill weight always exceeds the peptide it contains. Ask which number you are being quoted.
- Transit conditions. Heat exposure degrades peptides cumulatively and irreversibly. A cheaper vial that spent a week warm has lost value no discount recovers, and a pen — already in solution — is more exposed than sealed powder.
The same method applies across GLP-2 T, GLP-3 R, Tesamorelin, BPC-157, TB-500, Ipamorelin, Semax, MOTS-c, NAD+ and GHK-Cu. Supplier assessment generally is in choosing a research peptide supplier.
Storage consequences of the fatty-acid modification
The albumin-binding chain that makes this molecule usable also shapes how it behaves in storage.
A fatty acid is a lipophilic appendage on an otherwise polar peptide. That amphipathic character promotes association at interfaces — surfaces, air-liquid boundaries, container walls — which is the mechanism behind adsorptive loss in dilute solution. The effect scales inversely with concentration, so very dilute working solutions lose proportionally more than concentrated ones.
Two operational consequences follow. Prefer fewer, more concentrated preparations over many dilute ones. And treat agitation as a loss mechanism, not merely a denaturation risk — shaking multiplies interfacial area, which is precisely where an amphipathic molecule accumulates.
Beyond that, the compound follows conventional lyophilised-peptide practice, and the reasoning for each step is set out in reconstituting research peptides.
For the pen the material has been in solution since the fill, and at 31 residues with a modification there are more hydrolysis- and oxidation-susceptible sites than a short peptide presents. The fill date is therefore a substantive question rather than a formality — see pens versus vials.
Research use only
This document addresses composition, format, analytical verification and storage. It does not address administration, quantity or anticipated effect.
That boundary is deliberate and it is diagnostic. Material sold for research carries no approved indication, so quantities and outcomes cannot be substantiated by the party selling it. Regulatory action in this sector has proceeded on precisely that basis, and the determination turns on stated intended use across a vendor's whole presentation rather than on any single page.
The practical inference for a purchaser: a catalogue confining itself to composition and handling is operating as a research supplier. One describing physiological outcomes has adopted a different posture, and its analytical documentation should be evaluated with that in mind.
Frequently asked questions
What is semaglutide as a research peptide?
A 31-residue analogue of GLP-1 with a substitution that blocks enzymatic cleavage and a fatty-acid chain attached via a linker, which promotes reversible albumin binding and slows clearance.
Why does the fatty-acid modification matter for verification?
Because the molecular weight is the peptide backbone plus the fatty acid and linker. A certificate reporting a plain sequence and a mass calculated from it has been templated rather than analysed.
How does it differ from the dual and triple agonists?
Semaglutide engages the GLP-1 receptor only. The dual agonist adds GIP; the triple adds glucagon. Each addition is a harder synthesis problem, which is what the price ladder reflects.
Vial, pen or kit?
The vial for adjustable concentration and long storage, the pen for repeatable measurement without reconstitution, the kit for volume. Convert all three to cost per milligram before comparing.
What does 60mg/3ml work out to?
20mg/ml, fixed at manufacture and not adjustable.
Why does chain length affect what I should check?
Synthesis yield compounds across coupling steps, so longer peptides generate more deletion sequences. Those co-elute near the target, making the chromatogram and mass spectrometry more informative than the purity percentage alone.
Related research compounds
Further reading
Research use only. All products referenced on this page are sold strictly for laboratory and research purposes. They are not drugs, foods, cosmetics, or medical devices, and they are not intended to diagnose, treat, cure, or prevent any disease. They are not for human or veterinary consumption. Handling should be performed only by qualified individuals in an appropriate laboratory setting.